Answer
Although clinically relevant CYP-dependent interactions are considered unlikely, acoramidis inhibits CYP2C8 and CYP2C9 in vitro and no in vivo study has been performed, so concomitant substrates of these enzymes with a narrow therapeutic index should be used with caution.
Sources for this answer
- BEYONTTRA 356 mg film-coated tabletsBayer plc · emc · SmPC §4.5 Interaction with other medicinal products · Version 1Document updated
Sources checked